Empowered Funds LLC Increases Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Empowered Funds LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 315.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,064 shares of the biopharmaceutical company's stock after purchasing an additional 5,362 shares during the quarter. Empowered Funds LLC's holdings in Alnylam Pharmaceuticals were worth $1,943,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC raised its stake in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 143 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 30.3% during the first quarter. Acadian Asset Management LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $247,000 after buying an additional 386 shares during the period. O Shaughnessy Asset Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 9.6% in the first quarter. O Shaughnessy Asset Management LLC now owns 2,181 shares of the biopharmaceutical company's stock valued at $326,000 after acquiring an additional 191 shares in the last quarter. UniSuper Management Pty Ltd grew its holdings in Alnylam Pharmaceuticals by 100.0% during the 1st quarter. UniSuper Management Pty Ltd now owns 1,800 shares of the biopharmaceutical company's stock worth $269,000 after acquiring an additional 900 shares in the last quarter. Finally, National Bank of Canada FI increased its position in Alnylam Pharmaceuticals by 21,032.6% during the 1st quarter. National Bank of Canada FI now owns 108,410 shares of the biopharmaceutical company's stock valued at $16,312,000 after purchasing an additional 107,897 shares during the period. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $247.58 on Thursday. The stock's 50-day moving average is $273.83 and its two-hundred day moving average is $236.76. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same quarter last year, the firm earned $1.15 earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was down 33.3% on a year-over-year basis. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a research report on Friday, August 2nd. Raymond James raised their price target on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an "outperform" rating in a report on Friday, November 1st. Piper Sandler reiterated an "overweight" rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a report on Tuesday, November 12th. Finally, Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a "buy" rating in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.